102 related articles for article (PubMed ID: 7642466)
1. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.
Lum BL; Gosland MP
Hematol Oncol Clin North Am; 1995 Apr; 9(2):319-36. PubMed ID: 7642466
[TBL] [Abstract][Full Text] [Related]
2. Clinical studies with modulators of multidrug resistance.
Fisher GA; Sikic BI
Hematol Oncol Clin North Am; 1995 Apr; 9(2):363-82. PubMed ID: 7642468
[TBL] [Abstract][Full Text] [Related]
3. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
4. Molecular targets in oncology: implications of the multidrug resistance gene.
Lum BL; Gosland MP; Kaubisch S; Sikic BI
Pharmacotherapy; 1993; 13(2):88-109. PubMed ID: 8097038
[TBL] [Abstract][Full Text] [Related]
5. Modulators of multidrug resistance. Preclinical studies.
Ford JM
Hematol Oncol Clin North Am; 1995 Apr; 9(2):337-61. PubMed ID: 7642467
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
8. A role for P-glycoprotein in environmental toxicology.
Abu-Qare AW; Elmasry E; Abou-Donia MB
J Toxicol Environ Health B Crit Rev; 2003; 6(3):279-88. PubMed ID: 12746142
[TBL] [Abstract][Full Text] [Related]
9. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein activity and biological response.
Vaalburg W; Hendrikse NH; Elsinga PH; Bart J; van Waarde A
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):257-60. PubMed ID: 16043202
[TBL] [Abstract][Full Text] [Related]
12. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
13. Retroviral coexpression of two different types of drug resistance genes to protect normal cells from combination chemotherapy.
Suzuki M; Sugimoto Y; Tsukahara S; Okochi E; Gottesman MM; Tsuruo T
Clin Cancer Res; 1997 Jun; 3(6):947-54. PubMed ID: 9815770
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance in multiple myeloma.
Sonneveld P; Lokhorst HM; Vossebeld P
Semin Hematol; 1997 Oct; 34(4 Suppl 5):34-9. PubMed ID: 9408959
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic approaches to reversing multidrug resistance.
Sikic BI
Semin Hematol; 1997 Oct; 34(4 Suppl 5):40-7. PubMed ID: 9408960
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.
Mutoh K; Tsukahara S; Mitsuhashi J; Katayama K; Sugimoto Y
Cancer Sci; 2006 Nov; 97(11):1198-204. PubMed ID: 16925584
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
18. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells.
Brouillard F; Tondelier D; Edelman A; Baudouin-Legros M
Cancer Res; 2001 Feb; 61(4):1693-8. PubMed ID: 11245485
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
Cucco C; Calabretta B
Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
